Micro-CT combined with bioluminescence imaging: A dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model

Bone

Volumn 40, Issue 4, 2007, Pages 1032-1040

  Fritz, Vanessa ^a   Louis Plence, Pascale ^a   Apparailly, Florence ^a   Noël, Danièle ^a   Voide, Romain ^d   Pillon, Arnaud ^b   Nicolas, Jean Claude ^b   Müller, Ralph ^d   Jorgensen, Christian ^a,c  

^a HÔPITAL SAINT ELOI   (France)

^b INSERM   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d ETH ZURICH   (Switzerland)

Author keywords

Bioluminescence; Bone lesion; Micro computed tomography; Osteolytic tumor; Prostate cancer

Indexed keywords

LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BONE DENSITY; BONE DESTRUCTION; BONE MARROW; BONE METASTASIS; BONE MINERAL; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MONITORING; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SCID MOUSE; TIBIA; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; OSTEOLYSIS; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 33847758651     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.11.026     Document Type: Article

References (49)

1. Pinski J., and Dorff T.B. Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy. Eur. J. Cancer 41 (2005) 932-940
2. Roodman G.D. Mechanisms of bone metastasis. N. Engl. J. Med. 350 (2004) 1655-1664
3. So A., Gleave M., Hurtado-Col A., and Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J. Urol. 23 (2005) 1-9
4. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev., Cancer 2 (2002) 584-593
5. Keller E.T., Zhang J., Cooper C.R., Smith P.C., McCauley L.K., Pienta K.J., et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev. 20 (2001) 333-349
6. Yonou H., Kanomata N., Goya M., Kamijo T., Yokose T., Hasebe T., et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 63 (2003) 2096-2102
7. Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 107 (2001) 1235-1244
8. Clarke N.W., McClure J., and George N.J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol. 68 (1991) 74-80
9. Urwin G.H., Percival R.C., Harris S., Beneton M.N., Williams J.L., and Kanis J.A. Generalised increase in bone resorption in carcinoma of the prostate. Br. J. Urol. 57 (1985) 721-723
10. Rosol T.J., Tannehill-Gregg S.H., LeRoy B.E., Mandl S., and Contag C.H. Animal models of bone metastasis. Cancer 97 (2003) 748-757
11. Jenkins D.E., Yu S.F., Hornig Y.S., Purchio T., and Contag P.R. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin. Exp. Metastasis 20 (2003) 745-756
12. Zhau H.E., Li C.L., and Chung L.W. Establishment of human prostate carcinoma skeletal metastasis models. Cancer 88 (2000) 2995-3001
13. Schneider A., Kalikin L.M., Mattos A.C., Keller E.T., Allen M.J., Pienta K.J., et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 146 (2005) 1727-1736
14. Zhang J., Lu Y., Dai J., Yao Z., Kitazawa R., Kitazawa S., et al. In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer. Prostate 59 (2004) 360-369
15. Lee Y., Schwarz E., Davies M., Jo M., Gates J., Wu J., et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J. Orthop. Res. 21 (2003) 62-72
16. Corey E., Quinn J.E., Bladou F., Brown L.G., Roudier M.P., Brown J.M., et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52 (2002) 20-33
17. Soos G., Jones R.F., Haas G.P., and Wang C.Y. Comparative intraosseal growth of human prostate cancer cell lines LNCaP and PC-3 in the nude mouse. Anticancer Res. 17 (1997) 4253-4258
18. Contag C.H., Spilman S.D., Contag P.R., Oshiro M., Eames B., Dennery P., et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Photobiol. 66 (1997) 523-531
19. Edinger M., Hoffmann P., Contag C.H., and Negrin R.S. Evaluation of effector cell fate and function by in vivo bioluminescence imaging. Methods 31 (2003) 172-179
20. Tang Y., Shah K., Messerli S.M., Snyder E., Breakefield X., and Weissleder R. In vivo tracking of neural progenitor cell migration to glioblastomas. Hum. Gene Ther. 14 (2003) 1247-1254
21. Wetterwald A., van der Pluijm G., Que I., Sijmons B., Buijs J., Karperien M., et al. Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am. J. Pathol. 160 (2002) 1143-1153
22. Sweeney T.J., Mailander V., Tucker A.A., Olomu A.B., Zhang W., Cao Y., et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12044-12049
23. Edinger M., Sweeney T.J., Tucker A.A., Olomu A.B., Negrin R.S., and Contag C.H. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia 1 (1999) 303-310
24. Angelucci A., Gravina G.L., Rucci N., Festuccia C., Muzi P., Vicentini C., et al. Evaluation of metastatic potential in prostate carcinoma: an in vivo model. Int. J. Oncol. 25 (2004) 1713-1720
25. Arrington S.A., Schoonmaker J.E., Damron T.A., Mann K.A., and Allen M.J. Temporal changes in bone mass and mechanical properties in a murine model of tumor osteolysis. Bone 38 (2006) 359-367
26. Barck K.H., Lee W.P., Diehl L.J., Ross J., Gribling P., Zhang Y., et al. Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis. Arthritis Rheum. 50 (2004) 3377-3386
27. Muller R., Hannan M., Smith S.Y., and Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J. Bone Miner. Res. 19 (2004) 1787-1796
28. Filvaroff E.H., Guillet S., Zlot C., Bao M., Ingle G., Steinmetz H., et al. Stanniocalcin 1 alters muscle and bone structure and function in transgenic mice. Endocrinology 143 (2002) 3681-3690
29. Kurth A.A., and Muller R. The effect of an osteolytic tumor on the three-dimensional trabecular bone morphology in an animal model. Skelet. Radiol. 30 (2001) 94-98
30. Kapadia R.D., Stroup G.B., Badger A.M., Koller B., Levin J.M., Coatney R.W., et al. Applications of micro-CT and MR microscopy to study pre-clinical models of osteoporosis and osteoarthritis. Technol. Health Care 6 (1998) 361-372
31. Muller R. Bone microarchitecture assessment: current and future trends. Osteoporos. Int. 14 Suppl. 5 (2003) 89-99
32. Rubio N., Villacampa M.M., and Blanco J. Traffic to lymph nodes of PC-3 prostate tumor cells in nude mice visualized using the luciferase gene as a tumor cell marker. Lab. Invest. 78 (1998) 1315-1325
33. Berlin O., Samid D., Donthineni-Rao R., Akeson W., Amiel D., and Woods Jr. V.L. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer Res. 53 (1993) 4890-4895
34. Pillon A., Servant N., Vignon F., Balaguer P., and Nicolas J.C. In vivo bioluminescence imaging to evaluate estrogenic activities of endocrine disrupters. Anal. Biochem. 340 (2005) 295-302
35. Ruegsegger P., Koller B., and Muller R. A microtomographic system for the nondestructive evaluation of bone architecture. Calcif. Tissue Int. 58 (1996) 24-29
36. Hildebrand T., Laib A., Muller R., Dequeker J., and Ruegsegger P. Direct three-dimensional morphometric analysis of human cancellous bone: microstructural data from spine, femur, iliac crest, and calcaneus. J. Bone Miner. Res. 14 (1999) 1167-1174
37. Johnson C.S., Jerome C.P., and Brommage R. Unbiased determination of cytokine localization in bone: colocalization of interleukin-6 with osteoblasts in serial sections from monkey vertebrae. Bone 26 (2000) 461-467
38. Corey E., Quinn J.E., Emond M.J., Buhler K.R., Brown L.G., and Vessella R.L. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin. Cancer Res. 8 (2002) 1003-1007
39. El Hilali N., Rubio N., Martinez-Villacampa M., and Blanco J. Combined noninvasive imaging and luminometric quantification of luciferase-labeled human prostate tumors and metastases. Lab. Invest. 82 (2002) 1563-1571
40. Contag C.H., and Ross B.D. It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology. J. Magn. Reson. Imaging 16 (2002) 378-387
41. Ford-Hutchinson A.F., Cooper D.M., Hallgrimsson B., and Jirik F.R. Imaging skeletal pathology in mutant mice by microcomputed tomography. J. Rheumatol. 30 (2003) 2659-2665
42. David V., Lafage-Proust M.H., Laroche N., Christian A., Ruegsegger P., and Vico L. Two-week longitudinal survey of bone architecture alteration in the hindlimb-unloaded rat model of bone loss: sex differences. Am. J. Physiol.: Endocrinol. Metab. 290 (2006) E440-E447
43. Waarsing J.H., Day J.S., Verhaar J.A., Ederveen A.G., and Weinans H. Bone loss dynamics result in trabecular alignment in aging and ovariectomized rats. J. Orthop. Res. 24 (2006) 926-935
44. Sung S.Y., and Chung L.W. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting. Differentiation 70 (2002) 506-521
45. Bladou F., Gleave M.E., Penault-Llorca F., Serment G., Lange P.H., and Vessella R.L. In vitro and in vivo models developed from human prostatic cancer. Prog. Urol. 7 (1997) 384-396
46. Gujral A., Burton D.W., Terkeltaub R., and Deftos L.J. Parathyroid hormone-related protein induces interleukin 8 production by prostate cancer cells via a novel intracrine mechanism not mediated by its classical nuclear localization sequence. Cancer Res. 61 (2001) 2282-2288
47. Hart C.A., Scott L.J., Bagley S., Bryden A.A., Clarke N.W., and Lang S.H. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br. J. Cancer 86 (2002) 1136-1142
48. Lyon P.B., See W.A., Xu Y., and Cohen M.B. Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate 27 (1995) 179-186
49. Kim I.Y., Ahn H.J., Zelner D.J., Shaw J.W., Sensibar J.A., Kim J.H., et al. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res. 56 (1996) 44-48